RecruitingPhase 3NCT04766177
Role of Bumetanide in Treatment of Autism
Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children
Sponsor
Sherief Abd-Elsalam
Enrollment
80 participants
Start Date
Jan 1, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
Role of bumetanide in Autism
Eligibility
Min Age: 3 YearsMax Age: 12 Years
Inclusion Criteria2
- All patients with ASD diagnosed by CARS rating Scale⩾30.
- Age of patients range between (3-12) years.
Exclusion Criteria1
- Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBumetanide
bumetanide 0.5 mg twice daily
DRUGPlacebo
placebo tablets twice daily
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04766177
Related Trials
The Alama Project: Autism Outcomes and Neurobehavioral Markers in Young Children Born to Mothers With HIV in Kenya
NCT067031251 location
The Neurodevelopmental and Behavioral Phenotyping Screening Protocol
NCT002716221 location
Reciprocal Imitation Training and Musical Rhythm Sensitivity in Autistic Toddlers
NCT058802251 location
Evaluating Georgia Part C Implementation Outcomes
NCT071482581 location
Online Pivotal Response Treatment Training in Autism Spectrum Disorder
NCT065233871 location